

DAFTAR PUSTAKA

- ABIM, 2022. ABIM (American Board of Internal Medicine) Laboratory Test Reference Ranges–January 2022. Terdapat di: <https://www.abim.org/>.
- Ang, C.C. dan Tay, Y.K., 2011. Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. *Int J Dermatol*, 50(12), pp.1570–1578.
- Asati, D.P., Sharma, V.K., Khandpur, S., Khilnani, G.C. dan Kapil, A., 2011. Clinical and bacteriological profile and outcome of sepsis in dermatology ward in tertiary care center in New Delhi. *Indian J Dermatol Venereol Leprol*, 77(2), pp.141–147.
- Bastuji-Garin, S., Fouchard, N., Bertocchi, M., Roujeau, J.C., Revuz, J. dan Wolkenstein, P., 2000. Scortten: a severity-of-illness score for toxic epidermal necrolysis. *J Invest Dermatol*, 115(2), pp.149–153.
- Bolognia, J.L., Jorizzo, J.L. dan Schaffer, J. V, 2012. *Dermatology* 3 edn., USA: Elsevier Ltd.
- Cartotto, R., Mayich, M., Nickerson, D. dan Gomez, M., 2008. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. *J Burn Care Res*, 29(1), pp.141–146.
- Chandran, J., D'Silva, C., Sriram, S. dan Krishna, B., 2021. Clinical utility of arterial blood gas (ABG) test in an intensive care unit: an observational study. *Indian J Crit Care Med*, 25(2), pp.172–175.
- Dahlan, M.S., 2016. *Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan* 3rd edn., Jakarta: Salemba Medika.
- Devarbhavi, H. dan Raj, S., 2019. Drug-induced liver injury with skin reactions: drugs and host risk factors, clinical phenotypes and prognosis. *Liver Int*, 39(5), pp.802–811.
- Dilokthornsakul, P., Sawangjit, R., Inprasong, C., Chunhasewee, S., Rattanapan, R., Thooputra, T. *et al.*, 2016. Healthcare utilization and cost of Stevens-Johnson syndrome and toxic epidermal necrolysis management in Thailand. *J Postgrad Med*, 62(2), pp.109–114.
- Ducic, I., Shalom, A., Rising, W., Nagamoto, K. dan Munster, A.M., 2002. Outcome of patients with toxic epidermal necrolysis syndrome revisited. *Plast Reconstr Surg*, 110(3), pp.768–73.
- Finkelstein, Y., Macdonald, E.M., Li, P., Hutson, J.R. dan Juurlink, D.N., 2014. Recurrence and mortality following severe cutaneous adverse reactions. *JAMA*, 311(21), pp.2231–2232.
- Frantz, R., Huang, S., Are, A. dan Motaparthi, K., 2021. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. *Medicina (Kaunas)*, 57(9), p.895.
- Guégan, S., Bastuji-Garin, S., Poszepczynska-Guigné, E., Roujeau, J.C. dan Revuz, J., 2006. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. *J Invest Dermatol*, 126(2), pp.272–276.
- Guo, Z., Wang, G., Wu, B., Chou, W., Cheng, L., Zhou, C. *et al.*, 2020. DCAF1

- regulates Treg senescence via the ROS axis during immunological aging. *J Clin Invest*, 130(11), pp.5893–5908.
- Gupta, L.K., Martin, A.M., Agarwal, N., Souza, P.D., Das, S., Kumar, R. *et al.*, 2016. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: an Indian perspective. *Indian J Dermatol Venereol Leprol*, 82(6), pp.603–625.
- Gyawali, B., Ramakrishna, K. dan Dhamoon, A.S., 2019. Sepsis: the evolution in definition, pathophysiology, and management. *SAGE Open Med*, 7, pp.1–13.
- Halevy, S., Ghislain, P., Mockenhaupt, M., Fagot, J., Bavinck, J.N.B., Sidoroff, A. *et al.*, 2008. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. *J Am Acad Dermatol*, 58(1), pp.25–32.
- Harr, T. dan French, L.E., 2010. Toxic epidermal necrolysis and Stevens-Johnson syndrome. *Orphanet J Rare Dis*, 5, p.39.
- Heymann, W.R., 2021. SkinSerious: disseminated intravascular coagulation complicating Stevens-Johnson syndrome and toxic epidermal necrolysis. *J Am Acad Dermatol*, 84(4), pp.911–912.
- Hsu, D.Y., Brieva, J., Silverberg, N.B. dan Silverberg, J.I., 2016. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults. *J Invest Dermatol*, 136(7), pp.1387–1397.
- Hu, C.H., Chang, N.J., Liu, E.K.W., Chuang, S.S., Chung, W.H. dan Yang, J.Y., 2013. SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population. *J Eur Acad Dermatol Venereol*, 27(5), pp.628–633.
- Hung, C.C., Liu, W.C., Kuo, M.C., Lee, C.H., Hwang, S.J. dan Chen, H.C., 2009. Acute renal failure and its risk factors in stevens-johnson syndrome and toxic epidermal necrolysis. *Am J Nephrol*, 29(6), pp.633–638.
- Isaac, W.A., Damayanti, D., Fatimah, N. dan Hidayati, A.N., 2021. The profiles of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) patients in tertiary hospital. *Berkala Ilmu Kesehatan Kulit dan Kelamin*, 33(2), p.116.
- Kaimal, S., Lobo, C., Narayan, G. dan Augustine, M., 2023. Stevens-Johnson syndrome and toxic epidermal necrolysis: a fresh look at an old foe. *Indian J Dermatol*, 68(1), pp.34–40.
- Kelly, J.P., Auquier, A., Rzany, B., Naldi, L., Bastuju-Garin, S., Correia, O. *et al.*, 1995. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. *J Clin Epidemiol*, 48(9), pp.1099–108.
- Kim, G.H., Oh, K.H., Yoon, J.W., Koo, J.R., Kim, H.J., Chae, D.W. *et al.*, 2003. Impact of burn size and initial serum albumin level on acute renal failure occurring in major burn. *Am J Nephrol*, 23(1), pp.55–60.
- Kim, H.I., Kim, S.W., Park, G.Y., Kwon, E.G., Kim, H.H., Jeong, J.Y. *et al.*, 2012. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. *Korean J Intern Med*, 27(2), pp.203–210.
- Kinoshita, M., Ogawa, Y., Hama, N., Ujiie, I., Hasegawa, A., Nakajima, S. *et al.*,

2021. Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis. *Sci Transl Med*, 13(600):eaaz2398.
- Lee, T.H., Lee C., Ng, C., Chang, M., Chang, S., Fan, P. *et al.*, 2018. The influence of acute kidney injury on the outcome of Stevens–Johnson syndrome and toxic epidermal necrolysis: the prognostic value of KDIGO staging. *PLoS ONE*, 13(9), pp.1–12.
- Maemun, S., Mariana, N., Wijaya, S.O., Oktavia, D., Lisdawati, V. dan Rogayah, R., 2020. Is hypoalbuminemia a predictor marker of mortality? *Health Sci J Indones*, 11(2), pp.121–125.
- Malik, M.N., Mujeeb Ullah, A., Ahmad, M.E., Riaz, R. dan Syed, T.I.S., 2019. Pancytopenia in a patient with Stevens-Johnson syndrome: a case report with literature review. *Cureus*, 11(5), pp.5–11.
- Micheletti, R.G., Chiesa-Fuxench, Z., Noe, M.H., Stephen, S., Aleshin, M., Agarwal, A. *et al.*, 2018. Stevens-Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States. *J Invest Dermatol*, 138(11), pp.2315–2321.
- Mockenhaupt, M., 2017. Epidemiology of cutaneous adverse drug reactions. *Allergologie select*, 1(1), pp.96–108.
- Mockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J.N.B. *et al.*, 2008. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. *J Invest Dermatol*, 128(1), pp.35–44.
- Mockenhaupt, M. dan Roujeau, J.-C., 2019. Epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis). In S. Kang, M. Amagai, A. L. Bruckner, A. H. Enk, D. J. Margolis, A. J. McMichael, *et al.*, eds. *Fitzpatrick's Dermatology*. New York: McGraw-Hill Education, pp. 733–748.
- Noe, M.H., Rosenbach, M., Hubbard, R.A., Mostaghimi, A., Cardones, A.R., Chen, J.K. *et al.*, 2019. Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome/toxic epidermal necrolysis - ABCD-10. *JAMA Dermatol*, 155(4), pp.448–454.
- Oakley, A.M. dan Krishnamurthy, K., 2023. Stevens-Johnson syndrome. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing.
- Rahmasari, A.T., Indramaya, D.M., Lestari, P., 2019. Profile and treatment Steven Johnson syndrome patients in Dr. Soetomo General Hospital. *Nusantara Medical Science Journal*, 4(2), p.32.
- Riley, L.K. dan Rupert, J., 2015. Evaluation of patients with leukocytosis. *Am Fam Physician*, 92(11), pp.1004–1011.
- Roujeau, J.C., Kelly, J.P., Naldi, L., Rzany, B., Stern, R.S., Anderson, T. *et al.*, 1995. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. *N Engl J Med*, 333(24), pp.1600–7.
- Roujeau, J., 2013. Epidermal necrolysis (Stevens–Johnson syndrome and toxic epidermal necrolysis): historical considerations. *Dermatol Sin*, 31(4), pp.169–74.
- Rowling, S.C., Fløjstrup, M., Henriksen, D.P., Hallenberg, B.V.C., Lindholt, J.S., Alberg-Fløjborg, A. *et al.*, 2022. Arterial blood gas analysis: as safe as we think? A multicentre historical cohort study. *ERJ Open Res*, 8(1).

- Saguil, A. dan Fargo, M. V, 2020. Acute respiratory distress syndrome: diagnosis and management. *Am Fam Physician*, 101(12), pp.730–8.
- Schneider, J.A., Cohen, P.R., 2017. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. *Adv Ther*. 34(6), pp.1235-1244.
- Sekula, P., Dunant, A., Mockenhaupt, M., Naldi, L., Bavinck, J.N.B., Halevy, S. *et al.*, 2013. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. *J Invest Dermatol*, 133(5), pp.1197–1204.
- Shou, B., Li, J., Tang, C., Tan, Q., Zheng, D., Sun, B. *et al.*, 2017. The significance of changes in platelet concentration during the early phase after severe burn injury in a Chinese mass casualty. *Burns Trauma*, 5(1), pp.1–5.
- Spruance, S.L., Reid, J.E., Grace, M. dan Samore, M., 2004. Hazard ratio in clinical trials. *Antimicrob Agents Chemother*. 48(8), pp.2787–2792.
- Strużyna, J., Surowiecka, A., Korzeniowski, T., Korulczyk, P., Drozd, L., Stachura, A. *et al.*, 2022. Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis. *BMC Med Inform Decis Mak*, 22(1), pp.1–15.
- Sukasem, C., Katsila, T., Tempark, T., Patrinos, G.P. dan Chantratita, W., 2018. Drug-induced stevens-johnson syndrome and toxic epidermal necrolysis call for optimum patient stratification and theranostics via pharmacogenomics. *Annu Rev Genomics Hum Genet*, 19, pp.329–353.
- Thakur, V., Vinay, K., Kumar, S., Choudhary, R., Kumar, A., Parsad, D. *et al.*, 2021. Factors predicting the outcome of Stevens–Johnson syndrome and toxic epidermal necrolysis: a 5-year retrospective study. *Indian Dermatol Online J*, 12(2), pp.258–265.
- Torres-Navarro, I., Briz-Redón dan Botella-Estrada, R., 2020. Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol*, 34(9), pp.2066–2077.
- Trent, J.T., Kirsner, R.S., Romanelli, P. dan Kerdel, F.A., 2004. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. *JAMA Dermatol*, 140(7), pp.890–92.
- Ubukata, N., Nakatani, E., Hashizume, H., Sasaki, H. dan Miyachi, Y., 2023. Risk factors and drugs that trigger the onset of Stevens–Johnson syndrome and toxic epidermal necrolysis: a population-based cohort study using the Shizuoka Kokuho database. *JAAD Int*, 11, pp.24–32.
- Villanueva-Paz, M., Niu, H., Segovia-Zafra, A., Medina-Caliz, I., Sanabria-Cabrera, J., Isabel Lucena, M. *et al.*, 2021. Critical review of gaps in the diagnosis and management of drug-induced liver injury associated with severe cutaneous adverse reactions. *J Clin Med*, 10(22).
- Wang, L., Varghese, S., Bassir, F., Lo, Y.C., Ortega, C.A., Shah, S. *et al.*, 2022. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed/MEDLINE case reports from 1980 to 2020. *Front Med*, 9, pp.1–18.
- Wang, L.L., Noe, M.H. dan Micheletti, R.G., 2022. Prevalence of leukopenia and

- associated outcomes in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. *JAMA Dermatol*, 158(10), pp.1212–1214.
- Wasuwanich, P., So, J.M., Chakrala, T.S., Chen, J. dan Motaparathi, K., 2023. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. *JAAD Int*, 13, pp.17–25.
- Watanabe, T., Go, H., Saigusa, Y., Takamura, N., Watanabe, Y., Yamane, Y. *et al.*, 2021. Mortality and risk factors on admission in toxic epidermal necrolysis: a cohort study of 59 patients. *Allergol Int*, 70(2), pp.229–234.
- White, K.D., Abe, R., Ardern-Jones, M., Beachkofsky, T., Bouchard, C., Carleton, B. *et al.*, 2018. SJS/TEN 2017: building multidisciplinary networks to drive science and translation. *J Allergy Clin Immunol Pract*, 6(1), pp.38–69.
- Yang, M.S., Kang, M.G., Jung, J.W., Song, W.J., Kang, H.R., Cho, S.H. *et al.*, 2013. Clinical features and prognostic factors in severe cutaneous drug reactions. *Int Arch Allergy Immunol*, 162(4), pp.346–354.
- Zhang, Q., Shaikh, A.R., Yoon, T., Shah, S. dan Mahoney, J.W., 2021. The reflection on the management of toxic epidermal necrolysis in the community setting: an internist's perspective. *Cureus*, 13(1), pp.1–5.
- Zhang, Zhibin, Li, S., Zhang, Zhixiong, Yu, K. *et al.*, 2020. Clinical features, risk factors, and prognostic markers of drug-induced liver injury in patients with stevens-johnson syndrome/toxic epidermal necrolysis. *Indian J Dermatol Venereol Leprol*, 65(4), pp.274–278.
- Zimmerman, D. dan Dang, N.H., 2019. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): immunologic reactions. *Oncologic Critical Care*, 9, pp.267–80.